



## SEQUENCE LISTING

<110> Nycomed Imaging AS

<120> Improvements in or relating to  
diagnostic/therapeutic  
agents

<130> REF/Klaveness/054

<140> US 08/960,054

<141> 1997-10-29

<160> 25

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:RGDC-Mal-PEG3400-DSPE

<400> 1

Arg Gly Asp Cys

1

<210> 2

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Peptide  
comprising  
phosphatidylserine-binding and  
heparin-binding sections

<400> 2

Phe Asn Phe Arg Leu Lys Ala Gly Gln  
Lys Ile Arg Phe Gly Ala Ala

1 5  
10 15

Ala Trp Glu Pro Pro Arg Ala Arg Ile

20 25

<210> 3

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Heparin-binding  
peptide

<400> 3

Trp Glu Pro Pro Arg Ala Arg Ile

1 5

<210> 4

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Linker sequence

<220>

<221> MOD\_RES

<222> (1)

<223> MTX-phenylalanine

<400> 4

Phe Lys Leu Arg Leu Cys

1 5

<210> 5  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Heparin  
sulphate binding peptide

<400> 5  
Lys Arg Lys Arg

1

<210> 6  
<211> 8  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Fibronectin  
peptide

<400> 6  
Trp Gln Pro Pro Arg Ala Arg Ile

1            5

<210> 7  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
consisting of a heparin  
sulphate binding peptide  
and a fibronectin peptide

<220>  
<221> MOD\_RES

<222> (1)

<223> Dipalmitoyl-lysine

<400> 7

Lys Lys Arg Lys Arg Trp Gln Pro Pro  
Arg Ala Arg Ile

1 5  
10

<210> 8

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Fibronectin  
peptide sequence

<400> 8

Phe Asn Phe Arg Leu Lys Ala Gly Gln  
Lys Ile Arg Phe Gly Gly Gly

1 5  
10 15

Gly Trp Gln Pro Pro Arg Ala Ile

20

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Biotinylated  
endothelin-1 peptide

<220>

<221> MOD\_RES

<222> (1)

<223> Biotin-D-Trp

<400> 9

Trp Leu Asp Ile Ile Trp

1

5

<210> 10

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence: Biotinylated

fibrin-anti-polymerant peptide

<220>

<221> MOD\_RES

<222> (1)

<223> Biotinylated-Gly

<220>

<221> MOD\_RES

<222> (10)

<223> AMIDATION

<400> 10

Gly Pro Arg Pro Pro Glu Arg His Gln  
Ser

1

5

10

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence: Lipopeptide

containing RGD sequence and  
fluorescein reporter  
group

<220>

<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (4)  
<223> Acetyl-RGD-K-fluorescein side  
chain

<400> 11  
Lys Lys Lys Lys Gly

1 5

<210> 12  
<211> 18  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Endothelial  
cell binding lipopeptide

<220>  
<221> MOD\_RES  
<222> (1)  
<223> 2-n-hexadecylstearyl-Lys

<220>  
<221> MOD\_RES  
<222> (18)  
<223> AMIDATION

<400> 12  
Lys Leu Ala Leu Lys Leu Ala Leu Lys  
Ala Leu Lys Ala Ala Leu Lys  
1 5  
10 15

Leu Ala

<210> 13  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
functionalised with captopril

<220>  
<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (4)  
<223> Amide linked via side chain to  
captopril

<220>  
<221> MOD\_RES  
<222> (4)  
<223> AMIDATION

<400> 13  
Lys Lys Lys Lys

1

<210> 14  
<211> 13  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
with an affinity for  
endothelial cells

<220>  
<221> MOD\_RES  
<222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD\_RES

<222> (4)

<223> Acp

<220>

<221> MOD\_RES

<222> (13)

<223> AMIDATION

<400> 14

Lys Lys Lys Xaa Ile Arg Arg Val Ala

Arg Pro Pro Leu

1 5

10

<210> 15

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:Lipopeptide

comprising an interleukin-1

receptor binding

peptide

<220>

<221> MOD\_RES

<222> (1)

<223> Dipalmitoyl-Lys

<400> 15

Lys Gly Asp Trp Asp Gln Phe Gly Leu

Trp Arg Gly Ala Ala

1 5

10

<210> 16

<211> 12

<212> PRT



<213> Artificial Sequence

<220>

<221> MOD\_RES

<222> (1)

<223> Dabsyl-Tyr

<220>

<221> MOD\_RES

<222> (10)

<223> RGDS chain linked via NH2 group  
of lysine

<220>

<223> Description of Artificial

Sequence: Branched core

peptide comprising a dabsylated  
atherosclerotic

plaque-binding sequence and  
RGDS

<400> 16

Tyr Arg Ala Leu Val Asp Thr Leu Lys

Lys Gly Cys

1 5

10

<210> 17

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence: Synthetic

oligonucleotide

<220>

<221> misc\_feature

<222> (1)

<223> Biotinylated

<400> 17

gaaaggtagt ggggtcgtgt gccgg

25

<210> 18  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
with affinity for thrombi

<220>  
<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (15)  
<223> AMIDATION

<400> 18  
Lys Asn Asp Gly Asp Phe Glu Glu Ile  
Pro Glu Glu Tyr Leu Gln  
1 5  
10 15

<210> 19  
<211> 6  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide

<220>  
<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (5)  
<223> Biotinylated-Lys

<400> 19  
Lys Trp Lys Lys Lys Gly

1 5

<210> 20  
<211> 5  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Thiol-functionalised  
lipid molecule

<220>  
<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (4)  
<223> Acp

<400> 20  
Lys Lys Lys Xaa Cys

1 5

<210> 21  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
functionalised with atenolol

<220>  
<221> MOD\_RES  
<222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD\_RES

<222> (4)

<223> Lysine with side chain linked  
via amide bond to  
atenolol

<220>

<221> MOD\_RES

<222> (4)

<223> AMIDATION

<400> 21

Lys Lys Lys Lys

1

<210> 22

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Lipopeptide  
containing folic acid

<220>

<221> MOD\_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD\_RES

<222> (4)

<223> AMIDATION

<220>

<221> MOD\_RES

<222> (4)

<223> Lysine with side chain linked  
via amide bond to  
folic acid

<400> 22  
Lys Lys Lys Lys

1

<210> 23  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Lipopeptide  
containing a derivative of  
bestatin

<220>  
<221> MOD\_RES  
<222> (1)  
<223> Dipalmitoyl-Lys

<220>  
<221> MOD\_RES  
<222> (4)  
<223> AMIDATION

<220>  
<221> MOD\_RES  
<222> (4)  
<223> Lysine with side chain linked  
via amide bond to  
derivative of bestatin

<400> 23  
Lys Lys Lys Lys

1

<210> 24  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Lipopeptide  
containing chlorambucil

<220>

<221> MOD\_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD\_RES

<222> (4)

<223> AMIDATION

<220>

<221> MOD\_RES

<222> (4)

<223> Lysine with side chain linked  
via amide bond to  
chlorambucil

<400> 24

Lys Lys Lys Lys

1

<210> 25

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence:Lipopeptide  
functionalised with  
sulfoxazole

<220>

<221> MOD\_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD\_RES

<222> (4)

<223> AMIDATION

<220>

<221> MOD\_RES

<222> (4)

<223> Lysine with side chain linked  
via amide bond to  
sulfisoxazole

<400> 25

Lys Lys Lys Lys

1

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence: Atherosclerotic  
plaque-binding peptide

<400> 26

Tyr Arg Ala Leu Val Asp Thr Leu Lys

1

5

<210> 27

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial  
Sequence: Atherosclerotic  
plaque-binding peptide

<400> 27

Tyr Ala Lys Phe Arg Glu Thr Leu Glu  
Asp Thr Arg Asp Arg Met Tyr

1

5

10

15

<210> 28  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Atherosclerotic  
plaque-binding peptide

<400> 28  
Arg Ala Leu Val Asp Thr Glu Phe Lys  
Val Lys Gln Glu Ala Gly Ala  
1 5  
10 15

Lys

<210> 29  
<211> 14  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Thrombus  
binding peptide

<400> 29  
Asn Asp Gly Asp Phe Glu Glu Ile Pro  
Glu Glu Tyr Leu Gln  
1 5  
10

<210> 30  
<211> 4  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial  
Sequence:Thrombus



binding peptide

<400> 30

Gly Pro Arg Gly

1

<210> 31

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial

Sequence:Platelet

binding peptide

<400> 31

Pro Leu Tyr Lys Lys Ile Ile Lys Lys

Leu Leu Glu Ser

1

5

10